智通财经APP获悉，周五，Rani Therapeutics(RANI.US)飙升超265%，盘中一度熔断，股价创年内新高，报1.76美元。消息面上，该公司宣布与中外制药Chugai达成高达10.85亿美元的合作协议，获得1000万美元预付款，并有资格获得最高7500万美元技术转让与发展里程碑金、1亿美元销售里程碑金及个位数特许权使用费，同时中外制药有权选择扩展至5个额外药物靶点。Rani Therapeutics主营生物制品口服递送技术，核心平台RaniPill®专注于口服抗体及罕见病药物开发，此次合作应用于中外制药的罕见病抗体项目，验证技术应用价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.